Dividend puts strain on Pfizer

It's not a new question, but it's one whose urgency is growing: How long can Pfizer pay its big dividend? It's the largest in the industry, at 6.67 percent compared with 3.37 percent pharma-wide. And it cost the drugmaker $8 billion last year--at a time when the U.S. dollar is weak and the globalized Pfizer generates proportionately less money in the States.

Those are the costs. The benefits to Pfizer? Well, it's one of the few reasons folks are holding onto their shares. It's helped provide "a floor for the stock," someone close to Pfizer's board told the Wall Street Journal--and without that floor, the board worries, the price could drop to $10 or $12 from its current price of $19.18, already a 10-year low.

- read the story in the Wall Street Journal
- check out the Pharmalot post

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.